105728-02-7

Basic information

• Product Name: ethyl (3-formyl-4-nitrophenoxy)acetate
• Synonyms: acetic acid, 2-(3-formyl-4-nitrophenoxy)-, ethyl ester; Ethyl (3-formyl-4-nitrophenoxy)acetate
• CAS NO: 105728-02-7
• Molecular Formula: C₁₁H₁₁NO₆
• Molecular Weight: 253.2081
• Mol File: 105728-02-7.mol

Chemical Properties

• Boiling Point: 420.3°C at 760 mmHg
• Flash Point: 194.9°C
• Density: 1.333g/cm³
• Vapor Pressure: 2.85E-07mmHg at 25°C
• Refractive Index: 1.565
• CAS DataBase Reference: ethyl (3-formyl-4-nitrophenoxy)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl (3-formyl-4-nitrophenoxy)acetate(105728-02-7)
• EPA Substance Registry System: ethyl (3-formyl-4-nitrophenoxy)acetate(105728-02-7)

Safety Data

• Hazardous Substances Data: 105728-02-7(Hazardous Substances Data)

Upstream product

• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 138744-23-7 [3-(1,8-Dioxo-1,2,3,4,5,6,7,8,9,10-decahydro-acridin-9-yl)-4-nitro-phenoxy]-acetic acid ethyl ester 
• 112859-41-3 {3-[2,5-Dioxo-imidazolidin-(4Z)-ylidenemethyl]-4-nitro-phenoxy}-acetic acid ethyl ester 
• 105728-06-1 2-(3-formyl-4-nitrophenyl)oxyacetic acid 
• 105728-10-7 N-Cyclohexyl-2-(3-formyl-4-nitro-phenoxy)-N-methyl-acetamide 
• 105695-40-7 N-cyclohexyl-N-methyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxyacetamide 

Relevant articles and documents

Hapten synthesis, monoclonal antibody production and immunoassay development for direct detection of 4-hydroxybenzehydrazide in chicken, the metabolite of nifuroxazide

Derivatization is usually employed in immunoassay for detection of metabolites of nitrofurans and avoiding derivatization could be preferable to achieve an efficient screening. In the study, we designed four haptens of 4-hydroxybenhydrazide (HBH), the nifuroxazide metabolite. The effect of hapten structures on antibody affinity were evaluated and one monoclonal antibody was produced by using the Hapten C with a linear alkalane spacer arm. After optimization, an enzyme linked-immunosorbent assay (ELISA) was established with an 50% inhibition concentration of 0.25 ng mL?1 for HBH, which could ensure the direct detection of HBH without derivatization. The limit of detection of the ELISA for HBH was 0.12 μg kg?1 with the recoveries of 90.1–96.2% and coefficient of variation (CV) values lower than 9.1%. In conclusion, we produced several high affinity antibodies to HBH with new designed hapten and developed an icELISA for the direct detection of HBH without derivatization in chicken.

Nifuroxazide hapten, nifuroxazide artificial antigen, preparation method of artificial antigen and application of nifuroxazide hapten and artificial antigen

The invention relates to a nifuroxazide hapten, a nifuroxazide artificial antigen, a preparation method of the artificial antigen and application of the nifuroxazide hapten and nifuroxazide artificialantigen. The structure of the nifuroxazide hapten is shown in a formula (I) or formula (II), and the nifuroxazide artificial antigen is prepared through coupling of the hapten in the formula (I) or formula (II) and carrier protein. When the nifuroxazide artificial antigen is applied to immunity of animals, specific antibodies with high cost performance and high sensitivity can be obtained. A newway is provided for establishment of a fast, simple, inexpensive, sensitive and specific detection method of nifuroxazide through the nifuroxazide hapten and the antibodies which are prepared from thenifuroxazide hapten.

Nifuraldezone hapten and artificial antigen as well as preparation method and application thereof

The invention relates to nifuraldezone hapten and artificial antigen as well as a preparation method and application thereof. The nifuraldezone hapten has a structural formula (I) or (II) shown in thedescription. The nifuraldezone artificial antigen is prepared by coupling the hapten of the formula (I) or (II) with a carrier protein. When the nifuraldezone artificial antigen is adopted to immunize animals, specific antibodies with high valences and high sensitivity can be obtained. By adopting the nifuraldezone hapten and antibodies prepared from same, novel means for establishing rapid, simple, cheap, sensitive and specific nifuraldezone detection methods can be provided.

Inhibitors of Cyclic AMP Phosphodiesterase. 2. Structural Variations of N-Cyclohexyl-N-methyl-4-quinazolin-7-yl)oxy>butyramide (RS-82856)

A series of analogues of the cyclic AMP phosphodiesterase (PDE) inhibitor N-cyclohexyl-N-methyl-4-quinazolin-7-yl)oxy>butyramide (RS-82856, 1) was prepared by systematic variation of the side-chain substituent, length, position, connecting atom, and the parent heterocycle itself.The compounds were evaluated as inhibitors of cyclic AMP phosphodiesterase from both human platelets and rat or dog heart tissue and as inhibitors of ADP-induced platelet aggregation.Structure-activity correlations for the analogue series revealed significant limitations on the steric bulk of substituents on the 1,2,3,5-tetrahydroimidazoquinaazolin-2-one heterocycle and the position and length of the side-chain.As inhibitors of cyclic AMP phosphodiesterase (PDE), potency steadily increased with increasingly lipophilic side chains.In platelet aggregation inhibition studies, however, a maximum in activity was reached with 1, while more lipophilic compounds were significantly less active.Major changes in the heterocycle itself, represented by isomeric and other carbonyl variations, also decreased activity.The molecular features defined by this series of analogues of 1 correlate to a high degree with current understanding of thr chemical and topographical requirements of the active site of the FIII (type IV) form of cyclic AMP PDE.Selective inhibition of this enzyme has been proposed as the principal component of the positive inotropic action of a number of cardiotonic agents.